Carpentier-Edwards PERIMOUNT Aortic Heart Valve
Since its introduction in 1981, the PERIMOUNT valve technology has proven its long-term performance, based on key elements designed to optimize hemodynamics and valve durability
- Three independent symmetrical pericardial leaflets are matched for thickness and elasticity for long-term endurance and full valve opening
- Leaflets are mounted under the flexible stent to transfer stress during the cardiac cycle from the tissue to the stent
- Flexible cobalt-chromium stent absorbs and distributes stress evenly to minimize fatigue areas
Materials List
Valve leaflets: Bovine pericardium
Stent: Cobalt-chromium
Fabric covering stent: Polyester cloth
Valve sewing ring: Silicone rubber
Tissue Treatment
The PERIMOUNT aortic valve comes with the XenoLogiX treatment*, a two-step process targeting residual phospholipids (a known calcium binding sites), thus decreasing potential calcium uptake.
Progressive tissue calcification is indeed the main cause of failure of biological valves. By removing potential calcium binding sites, tissue treatment has been shown to reduce the risk of structural valve deterioration (SVD).
